TargetMol

Trifluridine

Product Code:
 
TAR-T1428
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1428-25mg25mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1428-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1428-50mg50mg£123.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1428-100mg100mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1428-200mg200mg£179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Trifluridine is a fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity.
CAS:
70-00-8
Formula:
C10H11F3N2O5
Molecular Weight:
296.202
Pathway:
Cell Cycle/Checkpoint; Microbiology/Virology; DNA Damage/DNA Repair
Purity:
0.9982
SMILES:
OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F
Target:
Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; HSV

References

1. Yamashita F, et al. Cancer Chemother Pharmacol,2015 Jun 18. 2. Sakamoto K, et al. Int J Oncol,2015, 46(6), 2327-2334. 3. Germano A, et al. Mol Cell Endocrinol. 2014 Jan 25;382(1):1-7. 4. Rootman DS, et al. Invest Ophthalmol Vis Sci,1989, 30(4), 678-683. 5. Tanaka N, et al. Oncol Rep,2014, 32(6), 2319-2326.